PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
77.26
-0.59 (-0.76%)
At close: Dec 5, 2025, 4:00 PM EST
77.15
-0.10 (-0.14%)
After-hours: Dec 5, 2025, 7:22 PM EST
PTC Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for PTC Therapeutics stock have an average target of 73.76, with a low estimate of 45 and a high estimate of 118. The average target predicts a decrease of -4.52% from the current stock price of 77.26.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for PTC Therapeutics stock from 17 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 6 | 6 | 6 | 6 | 7 | 6 |
| Hold | 3 | 3 | 3 | 3 | 4 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Total | 14 | 14 | 14 | 15 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy → Hold Downgrades $82 → $91 | Buy → Hold | Downgrades | $82 → $91 | +17.79% | Dec 1, 2025 |
| Barclays | Barclays | Hold Maintains $46 → $68 | Hold | Maintains | $46 → $68 | -11.98% | Nov 6, 2025 |
| Citigroup | Citigroup | Hold Maintains $50 → $75 | Hold | Maintains | $50 → $75 | -2.92% | Nov 5, 2025 |
| TD Cowen | TD Cowen | Hold Maintains $50 → $63 | Hold | Maintains | $50 → $63 | -18.45% | Nov 5, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $70 → $82 | Buy | Maintains | $70 → $82 | +6.14% | Nov 5, 2025 |
Financial Forecast
Revenue This Year
1.84B
from 806.78M
Increased by 128.32%
Revenue Next Year
1.00B
from 1.84B
Decreased by -45.49%
EPS This Year
9.47
from -4.73
EPS Next Year
-0.79
from 9.47
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.0B | 1.2B | ||||
| Avg | 1.8B | 1.0B | ||||
| Low | 1.7B | 788.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 152.2% | -33.3% | ||||
| Avg | 128.3% | -45.5% | ||||
| Low | 113.2% | -57.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 11.06 | 0.92 | ||||
| Avg | 9.47 | -0.79 | ||||
| Low | 8.36 | -3.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | -90.2% | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.